4x Blend GHRP-2 (5mg) / Tesamorelin (5mg) / MGF (.5mg) / Ipamorelin (2.5mg)

Research Applications

•  Investigating GH-mediated muscle hypertrophy and satellite cell activation in tissue engineering models.

•  Exploring fat metabolism and lipodystrophy reversal in metabolic disorder cell cultures.

•  Studying post-exercise recovery and anti-catabolic effects in myoblast proliferation assays.

•  Evaluating anti-aging mechanisms, including collagen synthesis and sleep regulation in neuronal models.

•  Probing synergistic GH secretagogue effects on appetite, energy homeostasis, and bone density in endocrine research.

Mechanisms of Action

•  GHRP-2: Acts as a ghrelin mimetic, binding to the growth hormone secretagogue receptor (GHSR) on pituitary somatotrophs to trigger pulsatile GH release via intracellular calcium mobilization and phospholipase C activation.

•  Tesamorelin: A synthetic analog of growth hormone-releasing hormone (GHRH), it binds GHRH receptors (GHRHR) on the anterior pituitary, increasing cAMP levels to promote GH gene transcription and sustained release.

•  MGF: As an alternative splice variant of IGF-1 (IGF-1Eb), it activates PI3K/Akt and MAPK pathways in muscle satellite cells, driving proliferation and migration for localized tissue repair without systemic GH elevation.

•  Ipamorelin: A selective GHSR agonist, it induces GH secretion through Gq-protein-coupled receptor signaling, emphasizing pituitary-specific effects with minimal impact on cortisol or prolactin.

Tesamorelin

Tesamorelin is a growth hormone-releasing factor analog primarily studied for reducing visceral adipose tissue in HIV patients with lipodystrophy. Here are key research studies:

•  Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data (2010): This pooled analysis of two phase-3 trials demonstrated significant reductions in visceral adipose tissue and improvements in lipid profiles.  Link

•  Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial (2014): A randomized trial showing tesamorelin reduced visceral and liver fat by 15-18% over 6 months, with benefits for metabolic health.  Link

•  The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV (2019): This study found tesamorelin improved body composition by reducing muscle fat infiltration and increasing muscle cross-sectional area.  Link

•  Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV (2020): Demonstrated a 40% relative reduction in hepatic fat, highlighting potential for treating NAFLD in HIV populations.  Link

•  Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy (2011): Review of randomized trials confirming safety and efficacy in reducing central fat accumulation.  Link

MGF (Mechano Growth Factor)

MGF, a splice variant of IGF-1, is researched for its roles in muscle repair, proliferation, and tissue regeneration post-injury. Key studies include:

•  Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? (2012): Comprehensive review on MGF’s specific actions in muscle development, growth, repair, and maintenance.  Link

•  The role of mechano growth factor in chondrocytes and cartilage defects (2023): Summarizes MGF’s involvement in cartilage repair at macroscopic and cellular levels, including proliferation and anti-apoptosis effects.  Link

•  Mechano growth factor, a splice variant of IGF-1, promotes neurogenesis by inducing astrocyte proliferation and apoptosis (2017): In vivo study in mice showing MGF enhances hippocampal neurogenesis via astrocyte modulation.  Link

•  Overexpression of Mechano-Growth Factor Modulates Inflammatory Reaction to Muscle Injury (2018): Examined MGF’s upregulation post-injury and its role in reducing inflammation and promoting regeneration.  Link

•  Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has independent functions in stimulating myogenesis and proliferation (2014): Highlighted IGF-1-independent effects of MGF on myoblast proliferation and differentiation.  Link

GHRP-2 (Growth Hormone Releasing Peptide-2)

GHRP-2 is a synthetic ghrelin mimetic studied for stimulating GH release, appetite, and potential therapeutic uses in GH deficiency. Selected key studies:

•  Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men (2005): Human study confirming GHRP-2’s orexigenic effects similar to ghrelin, with implications for appetite regulation.  Link

•  Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2 (GHRP-2) in growth-hormone-deficient children (1998): Early pharmacokinetic study supporting its use in pediatric GH therapy via subcutaneous administration.  Link

•  Growth hormone response to growth hormone-releasing peptide-2 (GHRP-2) in pituitary somatotroph adenoma cells (2012): Investigated direct GH-releasing effects in pituitary cells, independent of GHRH.  Link

•  Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects (2017): Broad review of GHRPs including GHRP-2’s anti-inflammatory and cardioprotective roles in preclinical models.  Link

•  Robust growth hormone responses to GH-releasing peptide 2 in children with idiopathic short stature (2024): Recent study validating GHRP-2 as a reliable GH provocation test in pediatric populations.  Link